Exploring the Adoption of Biosimilars in Saudi Arabia: Regulatory Framework and Healthcare Professional Perceptions

Abdulkarim Faleh Fihran Alanazi[1], Bassam saeed alshehri[2], Mohammed Nasser musfer alqahtani[3], Shorooq Eid Ayedh Albishi[4], Bushra abdullah alharbi[5], Meshari Bashir Rabea Alrashidi[6]

[1, 2, 3]Pharmacy Technician, [4]Laboratory technician, [5, 6]Pharmacist
King Abdulaziz Medical City Riyadh, Ministry of National Guard

Paper Publication Date: 15th February 2024

Abstract

The advent of biosimilars, highly similar versions of approved biological medicines, has revolutionized the pharmaceutical landscape, offering more affordable alternatives to expensive biologic therapies. As Saudi Arabia strives for equitable and sustainable healthcare delivery, the adoption of biosimilars has become a significant focus. This paper explores the current state of biosimilar adoption in Saudi Arabia, examining the regulatory framework and healthcare professionals' perceptions and attitudes. The Saudi Food and Drug Authority (SFDA) has established a comprehensive regulatory framework aligned with international best practices, ensuring biosimilars' safety, efficacy, and quality through rigorous evaluation processes, interchangeability and substitution guidelines, and specific naming and labeling requirements. However, studies have revealed knowledge gaps and mixed perceptions among healthcare professionals regarding biosimilars' long-term safety, efficacy, and interchangeability with reference biologics. Addressing these concerns through comprehensive education, transparent communication, and robust pharmacovigilance systems is crucial for fostering acceptance and appropriate use of biosimilars. Ultimately, a collaborative, multifaceted approach involving regulatory authorities, healthcare professionals, industry stakeholders, and patient organizations is essential for the successful integration of biosimilars in Saudi Arabia.

Introduction

The advent of biosimilars has revolutionized the pharmaceutical landscape, offering more affordable alternatives to expensive biologic medicines. As Saudi Arabia continues to enhance its healthcare infrastructure and strive for comprehensive, equitable, and sustainable healthcare delivery, the adoption of biosimilars has become a topic of significant interest and importance. This paper aims to explore the current state of biosimilar adoption in Saudi Arabia, delving into the regulatory framework governing their approval and use, as well as the perceptions and attitudes of healthcare professionals towards these innovative therapeutic alternatives.

Regulatory Framework for Biosimilars in Saudi Arabia

The Saudi Food and Drug Authority (SFDA) is the primary regulatory body responsible for overseeing the approval and monitoring of biological products, including biosimilars, in Saudi Arabia. The SFDA has

established a comprehensive regulatory framework to ensure the safety, efficacy, and quality of biosimilars entering the Saudi market.

1. Biosimilar Approval Process

The SFDA's guidelines for biosimilar approval are aligned with international best practices and guidelines set forth by organizations such as the World Health Organization (WHO) and the European Medicines Agency (EMA) (SFDA, 2017). The approval process involves a rigorous evaluation of the biosimilar candidate, including analytical characterization, non-clinical studies, and clinical studies designed to demonstrate biosimilarity to the reference biologic.

The SFDA requires biosimilar manufacturers to submit a comprehensive dossier containing data on the manufacturing process, quality control measures, analytical characterization, non-clinical studies, and clinical studies comparing the biosimilar to the reference biologic in terms of pharmacokinetics, pharmacodynamics, safety, and efficacy (SFDA, 2017). Additionally, the SFDA mandates post-marketing surveillance and risk management plans to monitor the safety and efficacy of approved biosimilars in real-world settings.

2. Interchangeability and Substitution

One of the key considerations in biosimilar adoption is the issue of interchangeability and substitution. Interchangeability refers to the ability to substitute a biosimilar for its reference biologic product or vice versa without compromising the safety or efficacy of the treatment (Kurki et al., 2017). In Saudi Arabia, the SFDA has established specific guidelines for interchangeability and substitution of biosimilars.

According to the SFDA's guidelines, biosimilars may be designated as interchangeable with their reference biologic products if they meet additional clinical data requirements demonstrating that the biosimilar can be safely and effectively substituted for the reference biologic without any clinically meaningful differences in safety, purity, or potency (SFDA, 2017). However, the final decision on whether to allow substitution between a biosimilar and its reference biologic rests with the prescribing healthcare professional, considering the patient's specific clinical condition and treatment history.

3. Naming and Labeling

The SFDA has established specific naming and labeling requirements for biosimilars to ensure clear identification and traceability. Biosimilars approved in Saudi Arabia are assigned unique non-proprietary names, known as International Non-proprietary Names (INNs), which are distinct from the reference biologic's INN (SFDA, 2017). This naming convention aims to prevent inadvertent substitution and facilitate pharmacovigilance activities.

Additionally, the SFDA mandates that biosimilar labeling includes clear statements indicating the product's biosimilarity status, the reference biologic product it is similar to, and any relevant safety information or precautions (SFDA, 2017). This labeling approach is designed to promote transparency and facilitate informed decision-making by healthcare professionals and patients.

Healthcare Professional Perceptions and Attitudes

The successful integration of biosimilars into clinical practice relies heavily on the acceptance and adoption by healthcare professionals, including physicians, pharmacists, and nurses. Their perceptions and attitudes towards biosimilars can significantly influence prescribing patterns, patient education, and ultimately, the uptake of these innovative therapies.

1. Knowledge and Awareness

Several studies have explored the knowledge and awareness levels of healthcare professionals in Saudi Arabia regarding biosimilars. A survey conducted by Al-Jedai et al. (2020) among physicians and pharmacists in Saudi Arabia revealed gaps in knowledge about biosimilars, with only 52% of respondents being familiar with the term "biosimilar." Another study by Omair et al. (2022) found that a significant proportion of rheumatologists lacked a comprehensive understanding of biosimilars, their regulatory pathways, and their potential benefits.

These findings highlight the need for ongoing education and training initiatives to enhance healthcare professionals' knowledge and awareness of biosimilars. A better understanding of biosimilars, their development processes, and regulatory frameworks can foster more informed decision-making and promote their appropriate use in clinical practice.

2. Perceptions and Attitudes

In addition to knowledge gaps, several studies have explored the perceptions and attitudes of healthcare professionals in Saudi Arabia towards biosimilars. A study by Qahtani et al. (2024) revealed that while healthcare professionals acknowledged the potential cost-saving benefits of biosimilars, they expressed concerns regarding the long-term safety and efficacy of these products, as well as the potential for immunogenicity and adverse events.

Similarly, a survey by Barbier et al. (2021) found that healthcare professionals in Saudi Arabia had mixed perceptions of biosimilars, with some expressing reservations about their efficacy, safety, and interchangeability with reference biologics. However, the study also highlighted the positive attitudes of healthcare professionals towards the potential cost savings and improved patient access associated with biosimilar adoption.

These findings underscore the importance of addressing concerns and misconceptions among healthcare professionals through comprehensive education and evidence-based information dissemination. Transparent communication and collaboration between regulatory authorities, industry stakeholders, and healthcare professionals can help build trust and confidence in biosimilars, ultimately facilitating their successful integration into clinical practice.

Opportunities and Challenges

The adoption of biosimilars in Saudi Arabia presents both opportunities and challenges that must be carefully considered and addressed to ensure a successful transition towards these innovative therapeutic alternatives.

1. Opportunities

a. Cost Savings and Improved Access: One of the primary opportunities associated with biosimilar adoption in Saudi Arabia is the potential for significant cost savings in healthcare expenditure. By providing more affordable alternatives to expensive biologic therapies, biosimilars can alleviate financial burdens on the healthcare system, payers, and patients, ultimately improving access to essential treatments.

b. Sustainable Healthcare Delivery: The implementation of biosimilars aligns with Saudi Arabia's vision for sustainable and equitable healthcare delivery. By reducing treatment costs and enabling broader access to biologic therapies, biosimilars can contribute to the long-term sustainability of the healthcare system while promoting better health outcomes for the population.

c. Fostering Competition and Innovation: The introduction of biosimilars can stimulate competition within the biopharmaceutical market, potentially driving innovation and further advancements in the development of new and improved biologic therapies.

2. Challenges

a. Regulatory Harmonization: While Saudi Arabia has established a comprehensive regulatory framework for biosimilars, there may be challenges in aligning with international best practices and ensuring harmonization across different regulatory bodies. Inconsistencies or discrepancies in regulatory requirements can create barriers to biosimilar adoption and hinder their availability in the Saudi market.

b. Healthcare Professional Education and Acceptance: As highlighted earlier, gaps in knowledge and concerns among healthcare professionals regarding biosimilars can pose significant challenges to their widespread adoption. Addressing these issues through comprehensive education, training, and evidence-based communication is crucial to foster acceptance and appropriate use of biosimilars in clinical practice.

c. Patient Awareness and Confidence: Patients' perceptions and level of confidence in biosimilars can influence their willingness to accept these treatments. Effective patient education and communication strategies are necessary to address concerns, dispel misconceptions, and promote informed decision-making regarding biosimilar use.

d. Pharmacovigilance and Post-Marketing Surveillance: Robust pharmacovigilance and post-marketing surveillance systems are essential to monitor the safety and efficacy of biosimilars in real-world settings. Ensuring the implementation of rigorous monitoring protocols and reporting mechanisms is crucial for maintaining public trust and addressing any potential safety concerns that may arise.

e. Supply Chain Management and Availability: Ensuring a consistent and reliable supply of biosimilars is a critical challenge that must be addressed. Supply chain management, including procurement, distribution, and inventory control, plays a vital role in ensuring the uninterrupted availability of biosimilars to healthcare facilities and patients.

Strategies for Successful Biosimilar Adoption

To overcome the challenges and capitalize on the opportunities presented by biosimilars, a multifaceted approach involving various stakeholders is essential. Here are some strategies that can facilitate the successful adoption of biosimilars in Saudi Arabia:

1. Healthcare Professional Education and Training

Implementing comprehensive education and training programs for healthcare professionals is crucial to bridging knowledge gaps and addressing concerns related to biosimilars. These initiatives should encompass the following aspects:

a. Collaboration with academic institutions and professional organizations to incorporate biosimilar education into medical, pharmacy, and nursing curricula, ensuring that future healthcare professionals receive comprehensive training on biosimilars.

b. Continuing medical education (CME) and professional development programs to update practicing healthcare professionals on the latest developments, regulatory guidelines, and clinical evidence related to biosimilars.

c. Dissemination of evidence-based information and guidelines from trusted sources, such as regulatory authorities, professional associations, and peer-reviewed publications, to promote a better understanding of biosimilars and their appropriate use.

d. Fostering open dialogue and discussion forums where healthcare professionals can engage with experts,

share experiences, and address concerns or misconceptions regarding biosimilars.

2. Patient Education and Awareness Campaigns

Engaging patients and the general public is crucial for fostering acceptance and confidence in biosimilars. Strategies for patient education and awareness campaigns may include:

a. Developing patient-friendly educational materials, such as brochures, videos, and online resources, that explain biosimilars in clear and accessible language, addressing common concerns and misconceptions.

b. Leveraging social media platforms and digital channels to disseminate accurate information and engage with patient communities, addressing their questions and concerns in real-time.

c. Collaborating with patient advocacy groups and support organizations to raise awareness about biosimilars and their potential benefits, fostering trust and confidence within patient communities.

d. Encouraging healthcare professionals to actively engage in patient education and counseling, ensuring that patients have a clear understanding of biosimilars and can make informed decisions about their treatment options.

3. Regulatory Harmonization and Collaboration

Promoting regulatory harmonization and collaboration at both national and international levels is essential for facilitating biosimilar adoption and ensuring consistent standards and practices. Potential strategies include:

a. Actively participating in international forums and initiatives aimed at aligning regulatory frameworks and guidelines for biosimilars, fostering a harmonized approach to their approval and monitoring.

b. Establishing collaborative partnerships and information-sharing mechanisms with regulatory authorities in other countries or regions, facilitating knowledge exchange and the adoption of best practices.

c. Engaging with industry stakeholders, healthcare professionals, and patient organizations to gather feedback and insights on the regulatory framework, enabling continuous improvement and adaptation to evolving needs and challenges.

4. Robust Pharmacovigilance and Post-Marketing Surveillance

Implementing robust pharmacovigilance and post-marketing surveillance systems is crucial for maintaining public trust and addressing any potential safety concerns related to biosimilars. Strategies may include:

a. Strengthening existing pharmacovigilance systems and adverse event reporting mechanisms to capture and analyze safety data related to biosimilars effectively.

b. Collaborating with healthcare professionals, industry stakeholders, and patient organizations to promote active participation in adverse event reporting and post-marketing surveillance activities.

c. Establishing dedicated biosimilar safety monitoring programs, including registries and patient follow-up studies, to gather real-world data on the long-term safety and efficacy of biosimilars.

d. Investing in data analytics and signal detection capabilities to identify and respond promptly to potential safety signals or adverse event patterns associated with biosimilar use.

5. Supply Chain Management and Access Initiatives

Ensuring a reliable and consistent supply of biosimilars, as well as improving patient access to these treatments, is essential for their successful adoption. Strategies may include:

a. Implementing robust supply chain management systems, including streamlined procurement processes, efficient distribution networks, and effective inventory control measures, to ensure the uninterrupted availability of biosimilars.

b. Collaborating with manufacturers, distributors, and healthcare facilities to identify and address potential supply chain bottlenecks or challenges that may impact biosimilar availability.

c. Developing strategic partnerships and agreements with biosimilar manufacturers to secure long-term supply commitments and facilitate competitive pricing for the Saudi market.

d. Exploring initiatives and programs aimed at improving patient access to biosimilars, such as reimbursement schemes, patient assistance programs, and innovative funding models, to alleviate financial barriers and promote equitable access to these treatments.

Conclusion

The adoption of biosimilars in Saudi Arabia represents a significant opportunity to enhance the sustainability and equity of healthcare delivery while providing more affordable and accessible treatment options for patients. The Saudi Food and Drug Authority has established a comprehensive regulatory framework aligned with international best practices, ensuring the safety, efficacy, and quality of biosimilars entering the Saudi market.

However, the successful integration of biosimilars into clinical practice requires addressing the knowledge gaps, perceptions, and concerns among healthcare professionals, as well as fostering patient awareness and confidence. Strategies such as comprehensive education and training initiatives, patient awareness campaigns, regulatory harmonization and collaboration, robust pharmacovigilance and post-marketing surveillance systems, and effective supply chain management and access initiatives are crucial to overcoming the challenges and capitalizing on the opportunities presented by biosimilars.

Ultimately, the successful adoption of biosimilars in Saudi Arabia hinges on a collaborative effort involving regulatory authorities, healthcare professionals, industry stakeholders, patient organizations, and the broader healthcare community. By fostering open communication, evidence-based decision-making, and a commitment to continuous improvement, Saudi Arabia can pave the way for the responsible and effective integration of biosimilars, contributing to the realization of a sustainable, equitable, and patient-centric healthcare system.

References

1. Alsultan, M. M., Baraka, M. A., Alahmari, A. K., Elrggal, M. E., Mahmoud, M. A., Alrasheed, M. A., ... & Alotaibi, M. M. (2024). Knowledge and Perception of Pharmacy Students toward Telepharmacy Education in Saudi Arabia. Healthcare, 12(18), 1806.
2. Barbier, L., Vandenplas, Y., Simoens, S., Declerck, P., Vulto, A. G., & Huys, I. (2021). Knowledge and perception of biosimilars in ambulatory care: a survey among Belgian community pharmacists and physicians. Journal of Pharmaceutical Policy and Practice, 14(1), 53. https://doi.org/10.1186/s40545-021-00330-x
3. Ismail, S., Abu Esba, L., Khan, M., Al-Abdulkarim, H., Modimagh, H., & Yousef, C. (2023). An institutional guide for formulary decisions of biosimilars. Hospital Pharmacy, 58(1), 38-48.
4. Kurki, P., van Aerts, L., Wolff-Holz, E., Giezen, T., Skibeli, V., & Weise, M. (2017). Interchangeability of biosimilars: a European perspective. BioDrugs, 31(2), 83-91.
5. Omair, M. A., Almadany, R., Omair, M. A., Al Rayes, H., Almalag, H. M., &Alshamsan, A. (2022). Perception of Biosimilar Biologics and Non-Medical Prescription Switching among Rheumatologists: A

Saudi Society for Rheumatology Initiative. Saudi Pharmaceutical Journal, 30(1), 39-44. https://doi.org/10.1016/j.jsps.2021.10.012

6. Qahtani, M. A., Al-Jedai, A., & Wertheimer, A. (2024). Factors that Influence Healthcare Professionals' Intentions towards Biosimilars. Innovations in Pharmacy, 15(1). https://doi.org/10.24926/iip.v15i1.5922
7. Rosembert, D. C., Twigg, M. J., & Wright, D. J. (2024). Patient's and Consultant's Views and Perceptions on Switching from an Originator Biologic to Biosimilar Medication: A Qualitative Study. Pharmacy, 12(2), 65. https://doi.org/10.3390/pharmacy12020065
8. Saudi Food and Drug Authority (SFDA). (2017). Guideline on Biosimilar Products Quality Considerations.